ENTRY       D09876                      Drug
NAME        Cariprazine hydrochloride (JAN/USAN);
            Vraylar (TN)
PRODUCT     VRAYLAR (Allergan)
            VRAYLAR (REMEDYREPACK)
FORMULA     C21H32Cl2N4O. HCl
EXACT_MASS  462.172
MOL_WEIGHT  463.8719
CLASS       Neuropsychiatric agent
             DG01478  Dopamine antagonist
              DG01474  Dopamine D2-receptor antagonist
            Metabolizing enzyme substrate
             DG01644  CYP2D6 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      ATC code: N05AX15
            Chemical structure group: DG01305
            Product (DG01305): D09876<US>
EFFICACY    Antipsychotic, Dopamine receptor partinal agonist, Serotonin receptor partial agonist/antagonist
  DISEASE   Schizophrenia [DS:H01649]
            Bipolar I disorder [DS:H01653]
TARGET      DRD2 [HSA:1813] [KO:K04145]
            HTR1A [HSA:3350] [KO:K04153]
            HTR2A [HSA:3356] [KO:K04157]
  PATHWAY   hsa04080(1813+3350+3356)  Neuroactive ligand-receptor interaction
            hsa04726(3350+3356)  Serotonergic synapse
            hsa04728(1813)  Dopaminergic synapse
METABOLISM  Enzyme: CYP3A4 [HSA:1576]; CYP2D6 [HSA:1565]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N05 PSYCHOLEPTICS
               N05A ANTIPSYCHOTICS
                N05AX Other antipsychotics
                 N05AX15 Cariprazine
                  D09876  Cariprazine hydrochloride (JAN/USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antipsychotics
              2nd Generation/Atypical
               Cariprazine
                D09876  Cariprazine hydrochloride (JAN/USAN)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01478  Dopamine antagonist
               DG01474  Dopamine D2-receptor antagonist
                DG01305  Cariprazine
                 D09876  Cariprazine hydrochloride
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG01305  Cariprazine
                D09876  Cariprazine hydrochloride
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG01305  Cariprazine
                 D09876  Cariprazine hydrochloride
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Dopamine
                DRD2
                 D09876  Cariprazine hydrochloride (JAN/USAN) &lt;US&gt;
               Serotonin
                HTR1A
                 D09876  Cariprazine hydrochloride (JAN/USAN) &lt;US&gt;
                HTR2A
                 D09876  Cariprazine hydrochloride (JAN/USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09876
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09876
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D09876
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01478  Dopamine antagonist
               DG01474  Dopamine D2-receptor antagonist
                DG01305  Cariprazine
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG01305  Cariprazine
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG01305  Cariprazine
DBLINKS     CAS: 1083076-69-0
            PubChem: 135626630
            ChEBI: 90932
            LigandBox: D09876
ATOM        29
            1   C1x C    20.7900  -19.3900
            2   C1y C    20.7900  -17.9900
            3   C1x C    22.0500  -17.2900
            4   C1x C    23.2400  -17.9900
            5   C1y C    23.2400  -19.3900
            6   C1x C    22.0500  -20.0900
            7   C1b C    24.5000  -20.0900
            8   C1b C    25.6900  -19.3900
            9   N1y N    26.8800  -20.0900
            10  C1x C    28.0700  -19.3900
            11  C1x C    29.2600  -20.0900
            12  N1y N    29.2600  -21.4900
            13  C1x C    28.0700  -22.1900
            14  C1x C    26.8800  -21.4900
            15  C8y C    30.5200  -22.2600
            16  C8y C    31.7100  -21.5600
            17  C8y C    32.9700  -22.2600
            18  C8x C    32.9700  -23.6600
            19  C8x C    31.7100  -24.3600
            20  C8x C    30.5200  -23.6600
            21  X   Cl   34.1600  -21.4900
            22  X   Cl   31.7100  -20.0900
            23  N1b N    19.6000  -17.2900
            24  C5a C    18.4100  -17.9900
            25  N1c N    17.2200  -17.2900
            26  O5a O    18.4100  -19.3900
            27  C1a C    16.0300  -17.9900
            28  C1a C    17.2200  -15.8900
            29  X   Cl   29.9600  -17.0100
BOND        30
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 1
            7     5   7 1 #Down
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11   10  11 1
            12   11  12 1
            13   12  13 1
            14   13  14 1
            15    9  14 1
            16   12  15 1
            17   15  16 2
            18   16  17 1
            19   17  18 2
            20   18  19 1
            21   19  20 2
            22   15  20 1
            23   17  21 1
            24   16  22 1
            25    2  23 1 #Up
            26   23  24 1
            27   24  25 1
            28   24  26 2
            29   25  27 1
            30   25  28 1
///
